▲ Peaking
Business
🔮 fades
Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says
The FDA has reversed its position on Regenxbio's gene therapy for MPS II, allowing a new path for accelerated approval.